

JosÃ© Ignacio Bernardino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8857207/publications.pdf>

Version: 2024-02-01

73
papers

1,503
citations

304743

22
h-index

361022

35
g-index

79
all docs

79
docs citations

79
times ranked

2368
citing authors

#	ARTICLE	IF	CITATIONS
1	Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. <i>Clinical Infectious Diseases</i> , 2021, 73, e4166-e4174.	5.8	135
2	Dual treatment with lopinavirâ€“ritonavir plus lamivudine versus triple treatment with lopinavirâ€“ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 785-792.	9.1	131
3	Sexualized Drug Use (Chemsex) Is Associated with High-Risk Sexual Behaviors and Sexually Transmitted Infections in HIV-Positive Men Who Have Sex with Men: Data from the U-SEX GESIDA 9416 Study. <i>AIDS Patient Care and STDs</i> , 2018, 32, 112-118.	2.5	84
4	Bone mineral density and inflammatory and bone biomarkers after darunavirâ€“ritonavir combined with either raltegravir or tenofovirâ€“emtricitabine in antiretroviral-naïve adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. <i>Lancet HIV</i> , the, 2015, 2, e464-e473.	4.7	69
5	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004â€“2013. <i>Journal of Infection</i> , 2016, 72, 587-596.	3.3	60
6	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. <i>Clinical Infectious Diseases</i> , 2013, 57, 112-121.	5.8	56
7	Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIVâ€“Positive Participants in the START (Strategic Timing of Antiretroviral) Tj ETQq1 1 0.784314 rg50 /Overl	1.0	43
8	Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. <i>Lancet HIV</i> , the, 2021, 8, e197-e205.	4.7	46
9	Educational Gradient in HIV Diagnosis Delay, Mortality, Antiretroviral Treatment Initiation and Response in a Country with Universal Health Care. <i>Antiviral Therapy</i> , 2012, 17, 1-8.	1.0	43
10	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. <i>Lancet HIV</i> , the, 2020, 7, e565-e573.	4.7	42
11	Prevalence of and risk factors for low bone mineral density in untreated <sc>HIV</sc> infection: a substudy of the <sc>INSIGHT</sc> Strategic Timing of AntiRetroviral Treatment (<sc>START</sc>) trial. <i>HIV Medicine</i> , 2015, 16, 137-146.	2.2	40
12	Prevalence of Abnormal Anal Cytology and High-Grade Squamous Intraepithelial Lesions Among a Cohort of HIV-Infected Men Who Have Sex With Men. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 475-481.	1.3	35
13	Visceral leishmaniasis as an independent cause of high immune activation, <sc>T</sc>â€“cell senescence, and lack of immune recovery in virologically suppressed <sc>HIV</sc>â€“coinfected patients. <i>HIV Medicine</i> , 2015, 16, 240-248.	2.2	34
14	Immediate Versus Deferred Switching From a Boosted Protease Inhibitorâ€“based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age â‰¥50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 597-606.	5.8	34
15	Impact of liver steatosis on the correlation between liver stiffness and fibrosis measured by transient elastography in patients coinfectd with human immunodeficiency virus and hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2011, 18, e278-83.	2.0	31
16	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab278.	0.9	31
17	Hypertension and Isolated Office Hypertension in HIV-Infected Patients Determined By Ambulatory Blood Pressure Monitoring: Prevalence and Risk Factors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 54-59.	2.1	28
18	Chems4EU: chemsex use and its impacts across four European countries in HIVâ€“positive men who have sex with men attending HIV services. <i>HIV Medicine</i> , 2021, 22, 944-957.	2.2	27

#	ARTICLE	IF	CITATIONS
19	Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine. <i>Lancet HIV</i> , 2022, 9, e438-e448.	4.7	27
20	Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 811-820.	5.8	26
21	Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. <i>HIV Medicine</i> , 2014, 15, 330-338.	2.2	25
22	Human papillomavirus mRNA testing for the detection of anal high-grade squamous intraepithelial lesions in men who have sex with men infected with HIV. <i>Journal of Medical Virology</i> , 2015, 87, 1397-1403.	5.0	24
23	Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naïve Adults Infected With HIV-1. <i>Journal of Infectious Diseases</i> , 2018, 218, 1523-1530.	4.0	22
24	Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults. <i>Journal of Infectious Diseases</i> , 2018, 218, 1531-1540.	4.0	22
25	Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy. <i>PLoS ONE</i> , 2013, 8, e69493.	2.5	22
26	HIV Replication, Inflammation, and the Effect of Starting Antiretroviral Therapy on Plasma Asymmetric Dimethylarginine, a Novel Marker of Endothelial Dysfunction. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, 128-134.	2.1	21
27	A Prospective Cohort Study of Neurocognitive Function in Aviremic HIV-Infected Patients Treated With 1 or 3 Antiretrovirals. <i>Clinical Infectious Diseases</i> , 2014, 59, 1627-1634.	5.8	19
28	Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 102-109.	2.1	19
29	Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial. <i>PLoS ONE</i> , 2019, 14, e0209911.	2.5	19
30	Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain. <i>HIV Clinical Trials</i> , 2015, 16, 57-65.	2.0	18
31	Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients. <i>Aids</i> , 2016, 30, 75-82.	2.2	16
32	Transient elastography to rule out esophageal varices and portal hypertensive gastropathy in HIV-infected individuals with liver cirrhosis. <i>Aids</i> , 2012, 26, 1807-1812.	2.2	15
33	Persistence of Novel First-Line Antiretroviral Regimes in a Cohort of HIV-Positive Subjects, Coris 2008-2010. <i>Antiviral Therapy</i> , 2013, 18, 161-170.	1.0	14
34	Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control. <i>Journal of Infectious Diseases</i> , 2022, 225, 1040-1049.	4.0	13
35	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2380-2393.	3.0	13
36	Innate and adaptive abnormalities in youth with vertically acquired HIV through a multicentre cohort in Spain. <i>Journal of the International AIDS Society</i> , 2021, 24, e25804.	3.0	13

#	ARTICLE	IF	CITATIONS
37	Determinants of blood telomere length in antiretroviral treatment-naïve <sc>HIV</sc>-positive participants enrolled in the <sc>NEAT</sc> 001/<sc>ANRS</sc> 143 clinical trial. HIV Medicine, 2019, 20, 691-698.	2.2	12
38	Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. Journal of Antimicrobial Chemotherapy, 2013, 68, 1373-1381.	3.0	11
39	Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study. BMC Infectious Diseases, 2014, 14, 379.	2.9	11
40	Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients. Liver International, 2020, 40, 2215-2227.	3.9	11
41	Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals. Journal of Viral Hepatitis, 2018, 25, 818-824.	2.0	10
42	Longitudinal Changes in Epigenetic Age Acceleration in Aviremic Human Immunodeficiency Virus-Infected Recipients of Long-term Antiretroviral Treatment. Journal of Infectious Diseases, 2022, 225, 287-294.	4.0	10
43	Detection and quantification of the K103N mutation in HIV reverse transcriptase by pyrosequencing. Diagnostic Microbiology and Infectious Disease, 2012, 72, 90-96.	1.8	8
44	Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: a detailed neuropsychological study. Journal of NeuroVirology, 2014, 20, 362-370.	2.1	8
45	Decreasing rates of acute myocardial infarction in people living with <sc>HIV</sc>: a nationwide cohort study in Spain, 2004-2015. HIV Medicine, 2018, 19, 491-496.	2.2	8
46	Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia. Aids, 2016, 30, 1141-1142.	2.2	7
47	Brief Report: Differential Effects of Tenofovir, Abacavir, Emtricitabine, and Darunavir on Telomerase Activity In Vitro. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 91-94.	2.1	7
48	Impact of HIV on the health-related quality of life in youth with perinatally acquired HIV. World Journal of Pediatrics, 2019, 15, 492-498.	1.8	7
49	Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients. Journal of Viral Hepatitis, 2020, 27, 955-958.	2.0	7
50	Clinical profile of eprosartan. Cardiovascular Drugs and Therapy, 2002, 16, 543-549.	2.6	6
51	Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy. Journal of the International AIDS Society, 2014, 17, 19544.	3.0	6
52	Effects of tenofovir on telomeres, telomerase and T cell maturational subset distribution in long-term aviraemic HIV-infected adults. Journal of Antimicrobial Chemotherapy, 2022, 77, 1125-1132.	3.0	6
53	The Pathophysiology of Hyperuricemia in Essential Hypertension: A Pilot Study. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1197-1199.	1.1	5
54	Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. Journal of Antimicrobial Chemotherapy, 2020, 75, 3334-3343.	3.0	5

#	ARTICLE	IF	CITATIONS
55	Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients. Journal of the International AIDS Society, 2014, 17, 19787.	3.0	4
56	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. Journal of Antimicrobial Chemotherapy, 2020, 75, 1955-1960.	3.0	4
57	Facial emotional processing deficits in long-term HIV-suppressed patients. Journal of the International AIDS Society, 2014, 17, 19664.	3.0	3
58	Carcinoma anal e infecci3n por el virus de la inmunodeficiencia humana: Â¿es la hora del cribado?. Revista Clinica Espanola, 2014, 214, 87-93.	0.6	3
59	Taking the long-view in a personalised approach to HIV care. Lancet HIV,the, 2017, 4, e483-e485.	4.7	3
60	Older HIV-infected adults: complex patientsâ€™ comorbidity (I). European Geriatric Medicine, 2019, 10, 189-197.	2.8	3
61	Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?. Aids, 2013, 27, 141-144.	2.2	2
62	Efficacy and Tolerability of Darunavir/Ritonavir in Combination with Abacavir/Lamivudine: An Option in Selected HIV-Infected Patients. HIV Clinical Trials, 2013, 14, 254-261.	2.0	2
63	Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort. Antiviral Therapy, 2021, 25, 335-340.	1.0	2
64	Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2022, 40, 121-124.	0.5	2
65	Past and future of HIV infection. A document based on expert opinion. Revista Espanola De Quimioterapia, 2022, 35, 131-156.	1.3	2
66	Metabolismo glucÃdico en la hipertensi3n arterial: papel de la sobrecarga oral de la glucosa. Medicina ClÃnica, 2006, 126, 116.	0.6	1
67	Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic Acid. Open Forum Infectious Diseases, 2016, 3, ofw041.	0.9	1
68	Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure. Journal of Antimicrobial Chemotherapy, 2021, 76, 1886-1892.	3.0	1
69	Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 29-32.	0.5	0
70	Abacavir/lamivudina + atazanavir no potenciado en la prÃctica clÃnica diaria: doce aÃ±os de experiencia. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 29-33.	0.5	0
71	8. Human papillomavirus mRNA testing for the detection of anal high-grade squamous intraepithelial lesions in HIV-positive men who have sex with men. Sexual Health, 2013, 10, 573.	0.9	0
72	Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2022, 40, 121-124.	0.3	0

#	ARTICLE	IF	CITATIONS
73	Proprotein convertase subtilisin/kexin type 9 inhibitors: a turning point in HIV-associated dyslipidemia?. Aids, 2022, 36, 745-747.	2.2	0